Loading…

Management of pediatric pemphigus vulgaris with rituximab: A case report and review of the literature

Pemphigus vulgaris (PV), an acquired autoimmune bullous disease, is caused by autoantibodies targeting desmosomal proteins in the skin and mucous membranes. Recent data from the adult PV population supports the use of rituximab, a chimeric anti‐CD20 IgG1 antibody, as a primary treatment strategy, bu...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric dermatology 2022-11, Vol.39 (6), p.960-966
Main Authors: Mistry, Bhavik Dipak, Leis, Maria, Lee, David Michael, Levy, Rebecca
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pemphigus vulgaris (PV), an acquired autoimmune bullous disease, is caused by autoantibodies targeting desmosomal proteins in the skin and mucous membranes. Recent data from the adult PV population supports the use of rituximab, a chimeric anti‐CD20 IgG1 antibody, as a primary treatment strategy, but limited data exist regarding treatment in the pediatric population. We report the case of a 13‐year‐old male with PV treated successfully with systemic corticosteroids and rituximab, and review the literature supporting the treatment of pediatric PV with rituximab.
ISSN:0736-8046
1525-1470
DOI:10.1111/pde.15095